NeueHealth (NEUE) Q4 2024 earnings summary

Executive summary

• Achieved strongest financial performance to date in 2024, driven by a value-driven, consumer-centric care model and operational efficiency.

• Served 483,000 consumers in 2024, with a 123% CAGR since 2020; started 2025 serving 717,000 consumers, a 48% increase over 2024.

• Positive Adjusted EBITDA for the fourth consecutive quarter, establishing a foundation for continued growth.

• Entered into a definitive agreement to be acquired by an affiliate of a major investor, with transaction expected to close in Q2 2025.

• Established a solid foundation for sustainable growth into 2025 and beyond.

Financial highlights

• Full year 2024 revenue was $936.7M; Q4 2024 revenue was $232.6M.

• Adjusted EBITDA for 2024 was $22.5M; Q4 Adjusted EBITDA was $5.5M, marking four consecutive quarters of profitability.

• Net loss from continuing operations for 2024 was $99.7M, a significant improvement from $627.7M in 2023.

• Net loss attributable to common shareholders for 2024 was $186.3M, improved from $1.2B in 2023.

• Cash and investments as of December 31, 2024: $202.8M; non-regulated cash and short-term investments: $93.2M, including $36.3M restricted.

Outlook and guidance

• Strategic focus in 2025 on expanding consumer reach in new and existing markets, diversifying product categories, and deepening presence in local communities.

• Plans to grow with existing and new payer partners and expand provider enablement offerings.

• Positioned for long-term, sustainable growth with a focus on profitable business segments and operational efficiency.

• Management believes the company is well-positioned for continued strong performance in 2025 and beyond.